Using advanced methodologies that pit drug compounds against specific types of malaria parasite cells, an international team of scientists have identified a new weapon and approach for attacking the parasites that cause malaria.
Principal investigator Elizabeth A Winzeler, from the University of California, San Diego and colleagues found a key metabolic enzyme (phosphatidylinositol 4-kinase or PI4K) that is used for intracellular development by Plasmodium species at each stage of infection in the vertebrate host.
"Most drugs selectively work on certain stages of the (parasite) life-cycle, but not all stages," said Case McNamara, the study's first author and a researcher at the Genomics Institute of the Novartis Research Foundation in San Diego.
Despite advances in prevention and treatment in recent years, malaria remains one of the world's great infectious scourges.
In 2010, according to the World Health Organisation, there were an estimated 219 million cases globally and 660,000 deaths, mostly among African children, researchers said.
The new approach is far more finely tuned, based on a series of detailed cellular assays that seek to model different parasite life-cycle stages in miniature test tubes.
A new chemical class, called imidazopyrazines, possessed these properties. The researchers then identified the protein target of these compounds as PI4K.
The disease is caused by Plasmodium parasites, which are transmitted to humans by the infectious bite of an Anopheles mosquito.
Plasmodium vivax and Plasmodium falciparum are the most problematic of the parasite species. The former is the most widespread globally; the latter most deadly.
The discovery could have significant ramifications for eventually eradicating malaria as a global disease.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
